IC-MPGN – Patient Worthy

Photo by Robina Weermeijer on Unsplash

Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN

Post author:Jessica Lynn
Post published:October 13, 2020
Post category:C3 Glomerulopathy Glomerulonephritis Proteinuria

According to a press release, biopharmaceutical company Apellis Pharmaceuticals ("Apellis") recently launched registration programs to explore pegcetacoplan for patients with C3 glomerulopathy (C3G), amyotrophic lateral sclerosis (ALS), and immune…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More